Journal
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
Volume 54, Issue 4, Pages 233-266Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10408363.2017.1313190
Keywords
Ovarian cancer; therapy; resistance; predictive biomarkers
Categories
Ask authors/readers for more resources
Therapy resistance is a major challenge in the management of ovarian cancer (OC). Advances in detection and new technology validation have led to the emergence of biomarkers that can predict responses to available therapies. It is important to identify predictive biomarkers to select resistant and sensitive patients in order to reduce important toxicities, to reduce costs and to increase survival. The discovery of predictive and prognostic biomarkers for monitoring therapy is a developing field and provides promising perspectives in the era of personalized medicine. This review article will discuss the biology of OC with a focus on targetable pathways; current therapies; mechanisms of resistance; predictive biomarkers for chemotherapy, antiangiogenic and DNA-targeted therapies, and optimal cytoreductive surgery; and the emergence of liquid biopsy using recent studies from the Medline database and ClinicalTrials.gov.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available